A. Kuromiya

Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.

M. Murata, B. Fujitani, J. Matsumoto, 1998, Journal of medicinal chemistry.

Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.

V. Bril, Y. Ono, K. Nakamura, 2009, Journal of pharmacological sciences.

Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.

V. Bril, Y. Ono, K. Nakamura, 2008, Journal of pharmacological sciences.

Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.

V. Bril, Y. Ono, K. Toyosawa, 2008, Journal of pharmacological sciences.

Development of a highly water-soluble peptide-based human neutrophil elastase inhibitor; AE-3763 for treatment of acute organ injury.

H. Okazaki, Y. Inoue, F. Sato, 2009, Bioorganic & medicinal chemistry.